Genes and Genetic Diseases

Chapter 4

Genes and Genetic Diseases

Lynn B. Jorde

In the nineteenth century, microscopic studies of cells led scientists to suspect that the nucleus of the cell contained the important mechanisms of inheritance. Scientists found that chromatin, the substance that gives the nucleus a granular appearance, is observable in nondividing cells (also see Chapter 6). Just before the cell divides, the chromatin condenses to form microscopically observable, threadlike structures called chromosomes. (Cell division and chromosomes are discussed in Chapter 1.) With the rediscovery of Gregor Mendel’s important breeding experiments at the turn of the twentieth century, it soon became apparent that the chromosomes contained genes, the basic units of inheritance. Genes are composed of sequences of deoxyribonucleic acid (DNA), a primary constituent of chromosomes; the other primary constituent consists of proteins, such as histones, that cause the DNA to coil into a highly compressed structure (Figure 1-2, Chapter 1). By serving as the blueprints of proteins in the body, genes ultimately influence all aspects of body structure and function. Humans have approximately 20,000 to 25,000 genes. An error in one of these genes can lead to a recognizable genetic disease. The composition of genes at a given locus is known as the genotype. The outward appearance of an individual, which is the result of both genotype and environment, is the phenotype (p. 151).

To date, more than 21,000 human genetic traits have been identified and cataloged.1 About one third of pediatric inpatients are children with genetic diseases.2 In addition, many common diseases that affect primarily adults, such as hypertension, coronary heart disease, diabetes, and cancer, are now known to have important genetic components. (These diseases are also affected by environmental factors. The interaction between genetic and environmental components is discussed in Chapter 5.)

Great progress is being made in the diagnosis of genetic diseases and the understanding of genetic mechanisms underlying them. Genetic testing is used increasingly to guide drug choice and dosage, and gene therapy—the direct alteration of genes in cells—is now carried out effectively for some diseases. Genetics is now one of the most rapidly advancing fields of medicine (Boxes 4-1 and 4-2).


The genetic causes of several thousand different diseases have now been identified and the pace of discovery is accelerating. Consequently, it is now possible to perform genetic tests to help determine whether an individual carries specific disease-causing mutations. Chromosome disorders, such as trisomy 21, are routinely detected using karyotypes or other, more automated approaches. More than 2700 diseases can now be diagnosed by testing for specific mutations ( In addition, genetic tests have been developed to help predict susceptibility for a number of common, genetically complex diseases.

Genetic testing can be applied in a variety of contexts, including:

1. Carrier screening. Genetic tests can identify heterozygous carriers for many recessive diseases, such as cystic fibrosis, sickle cell disease, and Tay-Sachs disease. It is becoming increasingly common for couples to undergo carrier screening to help make reproductive decisions, especially in populations in which specific diseases are relatively common (e.g., Tay-Sachs disease in the Ashkenazi Jewish population, β-thalassemia in Mediterranean populations). As a result, the prevalence of some of these diseases has declined dramatically in the past two decades.

2. Prenatal diagnosis. Several forms of prenatal genetic diagnosis are available, including:

a. Amniocentesis. This procedure, which is usually carried out at about 16 weeks’ gestation, involves the withdrawal of a small amount of amniotic fluid from the uterus. This fluid contains fetal cells, which can be cultured and karyotyped to detect chromosome abnormalities. In addition, genetic testing for single-gene disorders can be undertaken using DNA from these cells. Neural tube defects (spina bifida and anencephaly) can be detected as an elevation of α-fetoprotein level in amniotic fluid. Because there is a risk of fetal loss as a result of this procedure (estimated to be less than 1/200 above the background loss rate), it is usually recommended for women whose age is greater than 30 to 35 years or for couples who have a known increased risk of a specific genetic disease.

b. Chorionic villus sampling (CVS). Carried out at 10 to 12 weeks’ gestation, CVS is performed by extracting a small amount of villous tissue directly from the chorion. This procedure does not require in vitro culturing of cells for chromosome analysis because sufficient numbers are directly available in the extracted tissue. Chorionic villus sampling involves a slightly higher fetal loss rate (approximately 1%) than that of amniocentesis.

c. Preimplantation genetic diagnosis (PGD). This relatively new procedure is carried out on early embryos (typically 8 to 12 cells) created by in vitro fertilization. One or two cells are removed from the embryo (which causes no damage), and these cells can be tested for chromosome abnormalities or single-gene disorders. If a genetic disorder is found in the cell, the embryo is not implanted in the mother’s uterus.

d. Analysis of fetal DNA in maternal circulation. By approximately 6 to 8 weeks’ gestation, fetal cells can be found in the mother’s bloodstream and these cells (or cell-free fetal DNA) can be tested for some disease-causing mutations. This approach is still largely experimental, but it is developing rapidly and has the advantages of early diagnosis and minimal risk to the mother and fetus. In addition to these diagnostic procedures, prenatal screening is now routinely carried out by measuring various analytes in maternal serum samples to assess the risk of conditions, such as trisomy 21, 13, and 18, and neural tube defects. Newborn screening also is commonly performed for a variety of genetic conditions such as PKU and galactosemia. A positive screening result is an indication for a subsequent diagnostic test (e.g., amniocentesis for a positive prenatal screening result or DNA sequencing for a positive newborn screening result).

3. Presymptomatic diagnosis. Many hereditary diseases, such as familial breast or colon cancer, can be tested genetically before an individual develops the disease. For some of these conditions, measures can be taken either to diagnose the disease early (e.g., colonoscopy) or to minimize the risk of developing the disease.

4. Testing for drug efficacy or sensitivity. A number of genes are now known to be associated with sensitivity to specific therapeutic drugs, and people are sometimes tested for variants in these genes to help guide drug treatment. For example, abacavir, an antiviral drug used in treating human immunodeficiency virus (HIV) infection, can cause severe adverse reactions in those who have a specific HLA-B variant (HLA-B∗57:01), and the FDA now recommends testing for this variant before administering abacavir. For other drugs, such as warfarin, genetic testing for variants in specific genes (CYP2C9 and VKORC1) may help to guide drug dosage.

Although genetic testing can be very informative, it also has limitations. Genetic testing usually reveals the presence or absence of a disease-causing mutation, but many genetic diseases have incomplete penetrance. For example, a woman who carries a mutation in the BRCA1 or BRCA2 genes has a lifetime breast cancer risk of approximately 70% to 80% (but not 100%). In addition, the absence of a disease-causing mutation does not guarantee that the disease in question will not occur (e.g., a woman who does not have a BRCA1 or BRCA2 mutation still has nearly the same risk of developing breast cancer as do other women because these genes account for only a few percent of all cases of breast cancer). Individuals and families should be advised of these and other limitations of genetic testing.

Data from Harper JC, Sengupta SB: Hum Genet 131(2):175–186, 2012; South ST et al: Clin Obstet Gynecol 51(1):62–73, 2008.


Gene therapy, in which the harmful effects of a disease-causing mutation are corrected by altering the person’s DNA, has been a long-sought goal in human genetics. Hundreds of individuals are currently enrolled in dozens of clinical trials of gene therapy. Many technical challenges have arisen, but gene therapy is now beginning to yield positive therapeutic results.

In somatic cell gene therapy, the DNA of a specific set of an individual’s somatic cells is altered (it is also possible to perform germline therapy, which affects all cells, including reproductive cells; however, for technical and ethical reasons, this is not being pursued in humans). Most commonly, somatic cell therapy is used for conditions in which a mutation has caused the absence of a gene product in a cell (e.g., adenosine deaminase in T cells, which leads to immunodeficiency). A “vector” is used to carry a normal copy of the mutated gene into the individual’s cells. These vectors are usually viruses, such as retroviruses or adenoviruses, which have been genetically modified so that they contain the normal human gene and cannot make copies of themselves (otherwise they could cause a viral infection). Once inside the individual’s cells, the normal human gene begins to encode the missing gene product.

This approach faces a number of technical hurdles, including immune responses against the vector and difficulties in producing sufficient quantities of the desired gene product. In one case, an immune response against an adenoviral vector proved fatal, and several cases of leukemia have resulted from the insertion of a modified retrovirus near an oncogene. Nevertheless, gene therapy has now been successful in treating a number of inherited conditions, including two forms of severe combined immunodeficiency (SCID), β-thalassemia, and X-linked adrenoleukodystrophy. In some cases, symptoms have been completely reversed through gene therapy. In addition to the treatment of hereditary diseases, gene therapy is being used to alter tumor cells in the treatment of various types of cancer. It is hoped that further research will lead to safe, efficient, and cost-effective treatment of many human diseases through gene therapy.

Data from Kay MA: Nat Rev Genet 12(5):316–328, 2011.

DNA, RNA, and Proteins: Heredity at the Molecular Level


Composition and Structure

Genes are composed of DNA and the most important constituent of DNA is four types of nitrogenous bases (Figure 4-1). The four bases, adenine, cytosine, guanine, and thymine, are commonly represented by their first letters: A, C, G, and T, respectively.

In the early 1950s, James Watson and Francis Crick determined the physical structure of DNA. They proposed the now-famous double-helix model, in which DNA can be envisioned as a twisted ladder with chemical bonds as its rungs (see Figure 4-1). Projecting from each side of the ladder, at regular intervals, are the nitrogenous bases. The base projecting from one side is bound to the base projecting from the other by a weak hydrogen bond. Therefore, the nitrogenous bases form the rungs of the ladder; adenine pairs with thymine, and guanine pairs with cytosine. Each DNA subunit—consisting of one deoxyribose molecule, one phosphate group, and one base (see Figure 4-1)—is called a nucleotide.

DNA as the Genetic Code

To serve as the basis of genetic inheritance DNA must be able to provide a code for all the body’s proteins. Proteins are composed of one or more polypeptides (intermediate protein compounds), which are in turn composed of sequences of amino acids (organic acids containing NH2). The body contains 20 different types of amino acids, and the amino acid sequences that make up polypeptides must in some way be specified by the DNA molecule.

Because there are 20 possible amino acids and only four bases, each single nucleotide cannot specify an amino acid. Similarly, the amino acids cannot be specified by couplets of bases (e.g., adenine-guanine, thymine-guanine, guanine-cytosine) because there are only 4 × 4, or 16, possible couplets. If series of 3 bases are translated into amino acids, however, there are 4 × 4 × 4, or 64, possible combinations—more than enough to specify each different amino acid. By manufacturing synthetic nucleotide sequences and allowing them to direct the formation of amino acids in the laboratory, it was proved that amino acids were specified by these triplets of bases, or codons.

Of the 64 possible codons, three signal the end of a gene and are known as termination, or nonsense, codons. The remaining 61 all specify amino acids, which means that most amino acids can be specified by more than one codon. The genetic code is thus said to be redundant, although each codon can specify only one amino acid.

Another significant feature of the genetic code is that it is nearly universal: with the exception of ciliated protozoa and some plants, all organisms use precisely the same DNA codes to specify proteins. An important general exception to this rule occurs in mitochondria—cytoplasmic organelles that are the sites of cellular respiration (see Chapter 1). The mitochondria have their own extranuclear DNA. Several codons of mitochondrial DNA encode different amino acids than do the same nuclear DNA codons.


In addition to having the ability to specify amino acid sequences, DNA must be able to replicate itself accurately during cell division if it is to serve as the basic genetic material. DNA replication consists of the breaking of the weak hydrogen bonds between the bases, leaving a single strand with each base unpaired. The consistent pairing of adenine with thymine and of guanine with cytosine, known as complementary base pairing, is the key to accurate replication. The principle of complementary base pairing dictates that the unpaired base will attract a free nucleotide only if the nucleotide has the proper complementary base. Thus a portion of a single strand with a sequence of bases labeled ATTGCT will bond with a series of free nucleotides with the bases TAACGA. When replication is complete, a new double-stranded molecule identical to the original is formed (Figure 4-2, A). The single strand is said to be a template (guide), or molecule on which a complementary molecule is built, and is the basis for synthesizing the new double strand.

Several different proteins are involved in DNA replication. One protein unwinds the double helix, one holds the strands apart, and others perform different distinct functions. The most important of these proteins is the enzyme known as DNA polymerase. This enzyme travels along the single DNA strand, adding the correct nucleotides to the free end of the new strand (see Figure 4-2, B). Besides adding the new nucleotides, the DNA polymerase performs a proofreading procedure. After the new nucleotide has been added to the chain, the DNA polymerase checks to make sure that its base is actually complementary to the template base. If it is not, the incorrect nucleotide is excised and replaced with a correct one. This procedure, one of the mechanisms of DNA repair, substantially enhances the accuracy of DNA replication.


A mutation is any inherited alteration of genetic material. Microscopically observable alterations of chromosome number or structure are examples of mutations. Some mutations are much too small to be observed under a microscope. An example is the base pair substitution, in which one base pair is replaced by another. This mutation is sometimes called missense mutation because the “sense” of the codon produced after transcription of the mutant gene is altered (Figure 4-3). This substitution sometimes results in a change in amino acid sequence, but because of the redundancy of the genetic code, it may have no consequence. Profound consequences can result when an amino acid sequence is altered by a base pair substitution. (Many of the serious genetic diseases discussed later are the result of base pair substitutions.)

A second major type of mutation is the frameshift mutation. This alteration involves the insertion or deletion of one or more base pairs to the DNA molecule. As Figure 4-4 shows, these mutations can change the entire “reading frame” of the DNA sequence because codons consist of groups of three base pairs. A frameshift mutation thus can greatly alter the resulting amino acid sequence.

A large number of agents are known to increase the frequency of mutations. These agents are known collectively as mutagens. Radiation, such as that produced by x-rays and nuclear fallout, is an important mutagen and is known to cause cell damage (see Chapter 12). Radiation can fragment the DNA molecule and it can cause chemical reactions that can alter a DNA base. A variety of chemicals also can induce mutations, often because they are chemically similar to DNA bases. Other chemicals mimic the effects of ionizing radiation, and still others interfere with the process of base pairing. Hundreds of chemicals are now known to be mutagenic in humans or laboratory animals, such as nitrogen mustard, vinyl chloride, alkylating agents, formaldehyde, and sodium nitrite. Some of these chemicals, however, are much more potent mutagens than others. Nitrogen mustard, for example, is extremely mutagenic, whereas sodium nitrate is a weak mutagen.

Measurement of the mutation rate in humans is difficult, in part because mutations are very rare events. Current estimates are that the mutation rate in humans is about 10−4 to 10−7 per gene per generation. This rate appears to vary from one gene to another, with greater mutation rates for larger genes. At the nucleotide level, the human mutation rate is approximately 10−8 per nucleotide per generation. Certain DNA sequences have particularly high mutation rates and are known as mutational hot spots. In particular, sequences consisting of a cytosine base followed by a guanine base (CG) are highly susceptible to mutation and are known to account for a disproportionately large percentage of disease-causing mutations.3

From Genes to Proteins

Whereas DNA is formed and replicated in the cell nucleus, protein synthesis takes place in the cytoplasm. The transport of the DNA code from nucleus to cytoplasm and the subsequent protein formation involve two basic processes: transcription and translation. Both of these processes are mediated by ribonucleic acid (RNA), a type of nucleic acid that is chemically very similar to DNA. RNA differs from DNA in that uracil rather than thymine is one of the four nitrogenous bases. The other bases of RNA, as in DNA, are adenine, cytosine, and guanine. Uracil is structurally very similar to thymine, so it also can pair with adenine. Whereas DNA usually occurs as a double strand, RNA usually occurs as a single strand.


Transcription is the process by which RNA is synthesized from a DNA template. The result is the formation of messenger RNA (mRNA) from the base sequence specified by the DNA molecule. Transcription of a gene begins when an enzyme called RNA polymerase binds to a promoter site on the DNA. A promoter site is a sequence of DNA that specifies the beginning of a gene. In addition to RNA polymerase, proteins called transcription factors bind to DNA sequences called transcription factor binding sites near genes to regulate the timing of transcription, as well as the specific tissues in which genes are actively transcribed (e.g., clotting factor VIII primarily in hepatocytes) (Figure 4-5). Transcription factors can either activate or repress the expression of genes. In addition, transcription is sometimes up-regulated by the binding of nearby DNA sequences called enhancers. The RNA polymerase pulls a portion of the DNA strands apart from one another, allowing unattached DNA bases to be exposed. One of the DNA strands then provides the template for the sequence of mRNA nucleotides.

The sequence of bases in the mRNA is thus complementary to that of the template strand, and with the exception of the presence of uracil instead of thymine, the mRNA sequence is identical to that of the other DNA strand. Transcription continues until a DNA sequence called a termination sequence is reached. Then the RNA polymerase detaches from the DNA, and the transcribed mRNA is freed to move out of the nucleus and into the cytoplasm. Figure 4-6 summarizes the process of transcription.


Translation is the process by which RNA directs the synthesis of a polypeptide (Figure 4-7). However, mRNA cannot code directly for amino acids. Instead, it interacts with transfer RNA (tRNA), a cloverleaf-shaped strand of about 80 nucleotides. The tRNA molecule has a site for the attachment of an amino acid. At the opposite side of the cloverleaf is a sequence of three nucleotides called the anticodon. The anticodon undergoes complementary base pairing with an appropriate codon in the mRNA. The mRNA thus specifies the sequence of amino acids by acting through the tRNA. As each codon is processed, an amino acid is translated by the interaction of mRNA and tRNA, which is aided by cytoplasmic structures called ribosomes. Bonds are formed between adjacent amino acids to make a growing polypeptide. When the ribosome arrives at a termination signal on the mRNA sequence, translation and polypeptide formation cease. The mRNA, ribosome, and polypeptide separate from one another and the polypeptide is released into the cytoplasm to perform its required function.


Human cells can be categorized into two types: gametes (sperm and egg cells) and somatic cells, which include all cells other than gametes. Each somatic cell has 46 chromosomes in its nucleus. These are diploid cells, meaning that the chromosomes occur in pairs. Thus each cell actually contains 23 pairs of chromosomes. One member of each pair comes from an individual’s mother, and one comes from the father. New somatic cells are formed through mitosis and cytokinesis, through which the cell nucleus and cytoplasm are replicated. (The division process that creates new copies of somatic cells is described in Chapter 1.) Gametes are haploid cells: they have only one member of each chromosome pair, giving them a total of 23 chromosomes. The process by which these haploid cells are formed from diploid cells is called meiosis (Figure 4-8).

In 22 of the 23 chromosome pairs, the two members of each pair are virtually identical in microscopic appearance and DNA sequence and are thus said to be homologous to one another. These 22 chromosome pairs are homologous in both males and females and are termed autosomes. The remaining pair of chromosomes, the sex chromosomes, consists of two homologous X chromosomes in females and a nonhomologous pair, X and Y, in males.

Figure 4-9, A, illustrates a metaphase spread, which is a photograph of the chromosomes as they appear in the nucleus of a somatic cell during metaphase. (Chromosomes are easiest to visualize during this stage of mitosis.) A karyotype is an ordered display of chromosomes. In Figure 4-9, B, the chromosomes are arranged according to size, with the homologous chromosomes paired. The 22 autosomes are numbered according to length, with chromosome 1 as the longest and chromosome 22 as the shortest. Some natural variation in relative chromosome length can be expected from person to person, however, so it is not always possible to distinguish each chromosome by its length. Therefore, the position of the centromere is also used to classify the chromosomes (Figure 4-10).

The chromosomes in Figure 4-9, A, were stained with a substance that binds preferentially to certain areas of chromosomes. The resulting distinctive chromosome bands are evident in various patterns in the different chromosomes so that each chromosome can be distinguished easily. One of the most commonly used stains is Giemsa stain. By using banding techniques, chromosomes can be unambiguously numbered, and individual variation in chromosome composition can be studied. Missing or duplicated portions of chromosomes, which often result in serious diseases, also can be readily identified.

Chromosome Aberrations and Associated Diseases

Chromosome abnormalities are the leading known cause of mental retardation and miscarriage. A major chromosome aberration occurs in more than half of conceptions. Most of these fetuses do not survive to term; in fact, about 50% of all recovered first-trimester spontaneous abortuses have major chromosomal aberrations.4 About 1 in 150 live births has a major diagnosable chromosome abnormality.5


Cells that have a multiple of the normal number of chromosomes are said to be euploid cells (Greek eu = good or true). Because normal gametes are haploid and most normal somatic cells are diploid, they are both euploid forms. When a euploid cell has more than the diploid number of chromosomes, it is said to be a polyploid cell. Several types of body tissues, including some liver, bronchial, and epithelial tissues, are normally polyploid. A zygote having three copies of each chromosome, rather than the usual two, has a form of polyploidy called triploidy. Tetraploidy, a condition in which euploid cells have 92 chromosomes, also has been observed. Nearly all triploid and tetraploid conceptions are spontaneously aborted or stillborn, and the small proportion that survive to term die shortly after birth. Triploidy and tetraploidy are relatively common conditions at conception, accounting for approximately 10% of all known miscarriages.4


Aneuploid cells are defined as those that do not contain a multiple of 23 chromosomes. An aneuploid cell containing three copies of one chromosome is said to be trisomic (a condition termed trisomy). Monosomy, the presence of only one copy of a given chromosome in a diploid cell, is the other common form of aneuploidy. Among the autosomes, monosomy of any chromosome is lethal, but newborns with trisomy of chromosomes 13, 18, or 21 can survive. This difference illustrates an important principle: loss of chromosome material has more serious consequences than duplication of chromosome material.

Aneuploidy of the sex chromosomes is usually less serious than that of the autosomes. For the Y chromosome, this is true because very little genetic material is located on this chromosome. For the X chromosome, inactivation of extra chromosomes largely diminishes their effect. A zygote bearing no X chromosome, however, will not survive.

Aneuploidy is usually the result of nondisjunction, an error in which homologous chromosomes or sister chromatids fail to separate normally during meiosis or mitosis (Figure 4-11). Nondisjunction during either stage of meiosis produces some gametes that have two copies of a given chromosome and others that have no copies of the chromosome. When such gametes unite with normal haploid gametes, the resulting zygote is monosomic or trisomic for that chromosome.

Autosomal Aneuploidy

Trisomy can occur for any chromosome at conception, but the only forms seen with an appreciable frequency in live births are trisomies of the thirteenth, eighteenth, or twenty-first chromosome. Fetuses with most other chromosomal trisomies do not survive to term. Trisomy 16, for example, is the most commonly known trisomy among abortuses, but it is not seen in live births.4

Partial trisomy, in which only an extra portion of a chromosome is present in each cell, also can occur. The consequences of partial trisomies are not as severe as those of complete trisomies. Trisomies also may occur in only some cells of the body. Individuals thus affected are said to be chromosomal mosaics, meaning that the body has two or more different cell lines, each of which has a different karyotype. Mosaics are usually formed by early mitotic nondisjunction occurring in one embryonic cell but not in others.

The most well-known example of aneuploidy in an autosome is trisomy of the twenty-first chromosome, which causes Down syndrome (named after J. Langdon Down, who first described the disease in 1866). Down syndrome was formerly called mongolism, but this inappropriate term is no longer used. Down syndrome is seen in 1 in 800 live births.4 Individuals with this disease typically have intelligence quotients (IQs) between 25 and 70. The facial appearance is distinctive (Figure 4-12), with a low nasal bridge, epicanthal folds, protruding tongue, and flat, low-set ears. Poor muscle tone (hypotonia) and short stature are both characteristic. Congenital heart defects affect about one third to one half of live-born children with Down syndrome; a reduced ability to fight respiratory tract infections and an increased susceptibility to leukemia also contribute to reduced survival rate. By 40 years of age, individuals with Down syndrome virtually always develop symptoms that are nearly identical to those of Alzheimer disease because one of the genes that can cause Alzheimer disease is located on chromosome 21. About three fourths of fetuses known to have Down syndrome are spontaneously aborted or stillborn. About 20% of infants born with Down syndrome die during their first 10 years of life. For those who survive beyond 10 years, average life expectancy is now about 60 years.

About 97% of Down syndrome cases are caused by nondisjunction during the formation of one of the parent’s gametes or during early embryonic development. The remaining 3% result from translocations (discussed later). In approximately 90% to 95% of cases, the nondisjunction occurs in the formation of the mother’s egg cell. Paternal nondisjunction is responsible for the remaining cases. Among individuals with Down syndrome, about 1% are known to be mosaics. Because mosaics have a large number of normal cells, the effects of the trisomic cells are attenuated and symptoms are sometimes less severe.

The risk of having a child with Down syndrome increases greatly with maternal age. As Figure 4-13 demonstrates, women younger than 30 years have a risk ranging from about 1 in 1000 births to 1 in 2000 births. The risk begins to rise substantially after 35 years of age, and it reaches 3% to 5% for women older than 45 years of age. This dramatic increase in risk is a consequence of the age of maternal egg cells, which are held in an arrested state of prophase I from the time they are formed in the female embryo until they are shed in ovulation. Thus an egg cell formed by a 45-year-old woman is itself 45 years old. This long suspended state may allow for the accumulation of errors leading to nondisjunction. The risk of Down syndrome, as well as other trisomies, does not appear to increase with paternal age.6

Sex Chromosome Aneuploidy

Among live births, about 1 in 400 males and 1 in 650 females have a form of sex chromosome aneuploidy.7 Because these conditions are generally less severe than autosomal aneuploidies, all forms except complete absence of an X chromosome allow at least some individuals to survive.

One of the most common sex chromosome aneuploidies, affecting about 1 in 1000 newborn females, is trisomy X. Instead of two X chromosomes, these females have three X chromosomes in each cell. Most of them have no overt physical abnormalities, although sterility, menstrual irregularity, or cognitive deficits are sometimes seen. A very small proportion of females have four or even five X chromosomes, and their mental function is more severely compromised. Another sex chromosome aneuploidy is the presence of a single X chromosome and no homologous X or Y chromosome, resulting in a total of 45 chromosomes. The karyotype is designated 45,X, and it causes a set of symptoms known as Turner syndrome (Figure 4-14). Because they have no Y chromosome, only females are affected by Turner syndrome. They are usually sterile, however, and have gonadal streaks rather than ovaries. These streaks of connective tissue are susceptible to cancer in mosaics who have some cells containing a Y chromosome. Other features of the disorder include short stature, webbing of the neck in about half of cases, widely spaced nipples, coarctation (narrowing) of the aorta (in 15% to 20% of cases), edema of the feet in newborns, and sparse body hair. Their IQs are typically in the normal range, although they often have some impairment of spatial and mathematical reasoning ability. About three fourths of recognized 45,X conceptions inherit their X chromosome from the mother. Thus most cases are caused by a loss of the paternal X chromosome.

Sep 9, 2016 | Posted by in PATHOLOGY & LABORATORY MEDICINE | Comments Off on Genes and Genetic Diseases

Full access? Get Clinical Tree

Get Clinical Tree app for offline access
%d bloggers like this: